期刊
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
卷 45, 期 4, 页码 639-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.gtc.2016.07.003
关键词
Nonalcoholic fatty liver disease; NASH; Obesity; Hepatic steatosis; NASH therapeutics; Lipid droplet; Perilipins
资金
- Intercept
- NIH/NIAAA [K08-AA021424]
- Robert Wood Johnson Foundation
- Harold Amos Medical Faculty Development Award [7158]
- IDOM DRC Pilot Award [P30 DK019525]
- NIH/NIDDK [T32 DK007066]
- NIH [P30-DK050306]
Nonalcoholic fatty liver disease (NAFLD) is an important cause of morbidity and mortality worldwide and is rapidly becoming the leading cause of end stage liver disease and liver transplant. With a prevalence of 30% in the United States, it has reached epidemic proportions. The clinical syndrome of NAFLD spans from bland steatosis to steatohepatitis, which can progress to fibrosis and cirrhosis. The pathogenesis includes the roles of hormones, nutritional and intestinal dysbiosis, insulin resistance, lipotoxicity, hepatic inflammation, and genes. Noninvasive testing and liver biopsy indications are reviewed. Approved and investigational therapies for NAFLD and nonalcoholic steatohepatitis are outlined in this article.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据